| Literature DB >> 35729453 |
Judyta Juranek1, Konark Mukherjee2, Bernard Kordas3, Michał Załęcki4, Agnieszka Korytko3, Kamila Zglejc-Waszak3, Jarosław Szuszkiewicz5, Marta Banach6.
Abstract
This review reflects upon our own as well as other investigators' studies on the role of receptor for advanced glycation end-products (RAGE), bringing up the latest information on RAGE in physiology and pathology of the nervous system. Over the last ten years, major progress has been made in uncovering many of RAGE-ligand interactions and signaling pathways in nervous tissue; however, the translation of these discoveries into clinical practice has not come to fruition yet. This is likely, in part to be the result of our incomplete understanding of this crucial signaling pathway. Clinical trials examining the therapeutic efficacy of blocking RAGE-external ligand interactions by genetically engineered soluble RAGE or an endogenous RAGE antagonist, has not stood up to its promise; however, other trials with different blocking agents are being considered with hope for therapeutic success in diseases of the nervous system.Entities:
Keywords: Nervous system; Neurological disorders; Receptor for advanced glycation end-products; Sensorimotor disorders
Mesh:
Substances:
Year: 2022 PMID: 35729453 PMCID: PMC9554177 DOI: 10.1007/s12264-022-00878-x
Source DB: PubMed Journal: Neurosci Bull ISSN: 1995-8218 Impact factor: 5.271